Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients.
The effects of therapeutically relevant concentrations of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on the in vitro proteinase activity of Candida albicans were investigated with isolates from HIV-infected and uninfected patients with oral candidiasis. After exposure to the HIV proteinase inhibitors, proteinase activity was significantly reduced in a dose-dependent manner. These inhibitory effects, which were similar to that of pepstatin A, and the reduced virulence phenotype in experimental candidiasis after application of saquinavir indicate the usefulness of these HIV proteinase inhibitors as potential anticandidal agents.
Korting
H C
HC
Department of Dermatology, Ludwig-Maximilians-University, Munich, Germany.
Schaller
M
M
Eder
G
G
Hamm
G
G
Böhmer
U
U
Hube
B
B
D017088:AIDS-Related Opportunistic Infections / Q000382:microbiology*; D019380:Anti-HIV Agents / Q000494:pharmacology*; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors* / Q000302:isolation & purification / Q000378:metabolism; D002176:Candida albicans / Q000187:drug effects / Q000201:enzymology* / Q000302:isolation & purification; D002180:Candidiasis, Oral / Q000382:microbiology*; D004305:Dose-Response Relationship, Drug; D005656:Fungal Proteins / Q000037:antagonists & inhibitors; D015658:HIV Infections / Q000382:microbiology*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D006801:Humans; D019469:Indinavir / Q000494:pharmacology*; D010436:Pepstatins / Q000494:pharmacology; D019258:Saquinavir / Q000494:pharmacology*
D019380:Anti-HIV Agents; D005656:Fungal Proteins; D017320:HIV Protease Inhibitors; D010436:Pepstatins; C014195:Streptomyces pepsin inhibitor; D019469:Indinavir; D016282:Aspartic Acid Endopeptidases; D019258:Saquinavir; C031375:pepstatin